Page 1 of 41Free preview · 1–5

About this document

This 2024 Endocrine Society clinical practice guideline evaluates vitamin D supplementation and 25-hydroxyvitamin D testing for disease prevention using systematic reviews and GRADE methodology. It addresses 14 clinical questions and suggests empiric supplementation for children aged 1 - 18 years, adults aged 75 years and older, pregnant individuals, and adults with high-risk prediabetes alongside lifestyle modification. It suggests against supplementation above established dietary reference intakes in generally healthy adults younger than 75 and against routine vitamin D testing without established indications. Daily lower-dose supplementation is preferred over intermittent higher doses for adults aged 50 years and older when supplementation is indicated. Optimal supplementation doses and outcome-specific blood levels remain uncertain.

Free preview text

The first 5 pages, shown as text so search engines and readers can find this document.

Page 1

Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline Marie B. Demay,1 Anastassios G. Pittas,2 Daniel D. Bikle,3 Dima L. Diab,4 Mairead E. Kiely,5 Marise Lazaretti-Castro,6 Paul Lips,7 Deborah M. Mitchell,8 M. Hassan Murad,9 Shelley Powers,10 Sudhaker D. Rao,11,12 Robert Scragg,13 John A. Tayek,14,15 Amy M. Valent,16 Judith M. E. Walsh,17 and Christopher R. McCartney18,19 1Department of Medicine, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA 2Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Tufts Medical Center, Boston, MA 02111, USA 3Departments of Medicine and Dermatology, University of California San Francisco, San Francisco VA Medical Center, San Francisco, CA 94158, USA 4Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Cincinnati, Cincinnati, OH 45267, USA 5Cork Centre for Vitamin D and Nutrition Research, School of Food and Nutritional Sciences and INFANT Research Centre, University College Cork, Cork, T12 Y337, Ireland 6Department of Internal Medicine, Division of Endocrinology, Universidade Federal de Sao Paulo, Sao Paulo 04220-00, Brazil 7Endocrine Section, Amsterdam University Medical Center, Internal Medicine, 1007 MB Amsterdam, Netherlands 8Pediatric Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA 9Evidence-Based Practice Center, Mayo Clinic, Rochester, MN 55905, USA 10Bone Health and Osteoporosis Foundation, Los Gatos, CA 95032, USA 11Division of Endocrinology, Diabetes and Bone & Mineral Disorders, Henry Ford Health, Detroit, MI 48202, USA 12College of Human Medicine, Michigan State University, Lansing, MI 48824, USA 13School of Population Health, The University of Auckland, Auckland 1142, New Zealand 14Department of Internal Medicine, Harbor-UCLA Medical Center, Torrance, CA 90509, USA 15The Lundquist Institute, Torrance, CA 90502, USA 16Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, OR 97239, USA 17Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA 18Department of Medicine, University of Virginia, Charlottesville, VA 22908, USA 19Department of Medicine, West Virginia University, Morgantown, WV 26506, USA Correspondence: Marie B. Demay, MD, Professor of Medicine, Department of Medicine, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, 50 Blossom St, Thier 1113, Boston, MA 02114, USA. Email: mdemay@mgh.harvard.edu. Co-Sponsoring Organizations: American Association of Clinical Endocrinology (AACE), European Society of Endocrinology (ESE), Pediatric Endocrine Society (PES), American Society for Bone and Mineral Research (ASBMR), Vitamin D Workshop, American Society for Nutrition (ASN), Brazilian Society of Endocrinology and Metabolism (SBEM), Society of General Internal Medicine (SGIM), Endocrine Society of India (ESI) Abstract Background: Numerous studies demonstrate associations between serum concentrations of 25-hydroxyvitamin D (25[OH]D) and a variety of common disorders, including musculoskeletal, metabolic, cardiovascular, malignant, autoimmune, and infectious diseases. Although a causal link between serum 25(OH)D concentrations and many disorders has not been clearly established, these associations have led to widespread supplementation with vitamin D and increased laboratory testing for 25(OH)D in the general population. The benefit-risk ratio of this increase in vitamin D use is not clear, and the optimal vitamin D intake and the role of testing for 25(OH)D for disease prevention remain uncertain. Objective: To develop clinical guidelines for the use of vitamin D (cholecalciferol [vitamin D3] or ergocalciferol [vitamin D2]) to lower the risk of disease in individuals without established indications for vitamin D treatment or 25(OH)D testing. Methods: A multidisciplinary panel of clinical experts, along with experts in guideline methodology and systematic literature review, identified and prioritized 14 clinically relevant questions related to the use of vitamin D and 25(OH)D testing to lower the risk of disease. The panel prioritized randomized placebo-controlled trials in general populations (without an established indication for vitamin D treatment or 25[OH]D testing), evaluating the effects of empiric vitamin D administration throughout the lifespan, as well as in select conditions (pregnancy and prediabetes). The panel defined “empiric supplementation” as vitamin D intake that (a) exceeds the Dietary Reference Intakes (DRI) and (b) is implemented without testing for 25(OH)D. Systematic reviews queried electronic databases for publications related to these 14 clinical questions. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology was used to assess the certainty of evidence and guide recommendations. The approach incorporated perspectives from a patient representative and considered patient values, costs and resources required, acceptability and feasibility, and impact on health equity of the proposed recommendations. The process to develop this clinical guideline did not use a risk assessment framework and was not designed to replace current DRI for vitamin D. Received: 8 April 2024. Editorial Decision: 24 April 2024. Corrected and Typeset: 3 June 2024 © The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. See the journal About page for additional terms. The Journal of Clinical Endocrinology & Metabolism, 2024, 00, 1–41 https://doi.org/10.1210/clinem/dgae290 Advance access publication 3 June 2024 Clinical Practice Guideline

Page 2

Results: The panel suggests empiric vitamin D supplementation for children and adolescents aged 1 to 18 years to prevent nutritional rickets and because of its potential to lower the risk of respiratory tract infections; for those aged 75 years and older because of its potential to lower the risk of mortality; for those who are pregnant because of its potential to lower the risk of preeclampsia, intra-uterine mortality, preterm birth, small-for-gestational-age birth, and neonatal mortality; and for those with high-risk prediabetes because of its potential to reduce progression to diabetes. Because the vitamin D doses in the included clinical trials varied considerably and many trial participants were allowed to continue their own vitamin D–containing supplements, the optimal doses for empiric vitamin D supplementation remain unclear for the populations considered. For nonpregnant people older than 50 years for whom vitamin D is indicated, the panel suggests supplementation via daily administration of vitamin D, rather than intermittent use of high doses. The panel suggests against empiric vitamin D supplementation above the current DRI to lower the risk of disease in healthy adults younger than 75 years. No clinical trial evidence was found to support routine screening for 25(OH)D in the general population, nor in those with obesity or dark complexion, and there was no clear evidence defining the optimal target level of 25(OH)D required for disease prevention in the populations considered; thus, the panel suggests against routine 25(OH)D testing in all populations considered. The panel judged that, in most situations, empiric vitamin D supplementation is inexpensive, feasible, acceptable to both healthy individuals and health care professionals, and has no negative effect on health equity. Conclusion: The panel suggests empiric vitamin D for those aged 1 to 18 years and adults over 75 years of age, those who are pregnant, and those with high-risk prediabetes. Due to the scarcity of natural food sources rich in vitamin D, empiric supplementation can be achieved through a combination of fortified foods and supplements that contain vitamin D. Based on the absence of supportive clinical trial evidence, the panel suggests against routine 25(OH)D testing in the absence of established indications. These recommendations are not meant to replace the current DRIs for vitamin D, nor do they apply to people with established indications for vitamin D treatment or 25(OH)D testing. Further research is needed to determine optimal 25(OH)D levels for specific health benefits. Key Words: vitamin D, 25-hydroxyvitamin D, vitamin D deficiency, mortality, pregnancy, infection, prediabetes, clinical practice guidelines, systematic reviews Introduction The role of vitamin D in the regulation of skeletal and mineral ion homeostasis is well established. Epidemiologic evidence has shown consistent associations of low vitamin D status with increased risk of a variety of common disorders, includ- ing musculoskeletal, metabolic, cardiovascular, malignant, autoimmune, and infectious diseases (1-3,). However, obser- vational studies are prone to confounding and various forms of bias, and a causal link between low vitamin D status, as as- sessed by serum 25-hydroxyvitamin D (25[OH]D) levels, and many disorders has not been clearly established. Nonetheless, these associations have led to widespread supplementation and increased laboratory testing for 25(OH)D levels in the general population. In the United States, the prevalence of supplemental vitamin D use of 1000 IU (25 μg) or more per day increased from 0.3% in the 1999-2000 National Health and Nutrition Examination Survey (NHANES) to 18.2% in the 2013-2014 NHANES (4). The use of 25(OH)D testing in clinical practice has also been increasing; however, the cost- effectiveness of widespread testing has been questioned, espe- cially given the uncertainty surrounding the optimal level of 25(OH)D required to prevent disease. Vitamin D is not a true vitamin (defined as a nutrient that cannot be endogenously synthesized), as intake is not required in those who have adequate sun exposure. However, seasonal variation in UV-B availability and decreased sun exposure as- sociated with clothing and limited time outdoors has resulted in the general population being increasingly reliant on oral in- take of vitamin D in a few natural sources, foods fortified with vitamin D, and supplements containing vitamin D. Whether ingested or synthesized in the skin, vitamin D is converted to 25(OH)D in the liver (5). This process is not tightly regulated; therefore, the 25(OH)D concentration most accurately reflects vitamin D status. A second hydroxylation step (1-alpha) leads to the formation of the active metabolite, 1,25-dihydroxyvita- min D in many tissues. Circulating 1,25-dihydroxyvitamin D is thought to derive primarily from renal 1-alpha hydroxylation in the absence of pathologic conditions (6). Although loss of function mutations in vitamin D hydroxylases are rare, genetic variants and several pharmacologic agents may affect their ac- tivity (7-10). Vitamin D metabolites are secreted with bile acids and reabsorbed in the terminal ileum; therefore, terminal ileal disease, as well as general malabsorption and having a short gut (including from Roux-en-Y gastric bypass), can lead to low levels of serum 25(OH)D. There are other conditions that place individuals at risk for low 25(OH)D levels. For ex- ample, vitamin D metabolites bound to vitamin D–binding protein and albumin are lost in the urine of those with nephrot- ic syndrome. In addition, vitamin D metabolites are inacti- vated primarily by the 24-hydroxylase, which is induced by high levels of 1,25-dihydroxyvitamin D as well as by fibroblast growth factor-23, as seen in chronic kidney disease (11). Importantly, these guidelines do not apply to individuals with such underlying conditions that substantially alter vita- min D physiology. The actions of vitamin D metabolites are mediated by the vitamin D receptor (VDR), which is expressed in most tissues. The VDR has been shown to regulate cellular differentiation and target gene expression in many cell types, including those of the immune system. The best-established physiologic role of the VDR is promoting intestinal calcium absorption, which is critical for maintaining skeletal and mineral ion homeostasis (12, 13). The skeletal effects of vitamin D are dependent on ad- equate calcium intake. The effects of vitamin D on the immune system are due to local activation of 25(OH)D to 1,25-dihydroxyvitamin D and induction of VDR expression (14). Thus, the optimal level of 25(OH)D to prevent disease likely depends on the clinical outcomes being evaluated. Similarly, the required duration of exposure to vitamin D for specific outcomes is expected to vary, depending on the under- lying pathophysiology (eg, acute [infections] vs chronic [cancer]). In contrast to previous guidelines that broadly addressed the evaluation, treatment, and prevention of vitamin D defi- ciency, with an emphasis on the care of patients who are at risk for deficiency (15), the goal of this Guideline Development Panel was to establish clinical guidelines for the use of vitamin D to lower the risk of disease in individuals without established indications for vitamin D treatment or 25(OH)D testing. The panel recognized that there are numer- ous important clinical questions regarding the use of vitamin D and 25(OH)D testing in the general population; however, due to limited resources, 14 of these clinical questions were prioritized and 4 to 6 outcomes were addressed for each ques- tion. Because patient-important clinical outcomes are 2 The Journal of Clinical Endocrinology & Metabolism, 2024, Vol. 00, No. 0

Page 3

expected to differ according to the target population, the pan- el proposed specific outcomes for the pediatric population (ages 1 to 18 years), and for ages 19 to 49 years, 50 to 74 years, and 75 years and older. Established guidelines recommend empiric vitamin D in the first year of life, specifically to prevent nutritional rickets (16-18); thus, this demographic was not ad- dressed. Other populations examined were pregnant individ- uals and those with prediabetes, dark complexion, and obesity. The panel also addressed whether daily supplementa- tion with vitamin D should be recommended rather than inter- mittent (nondaily), higher-dose vitamin D, and whether supplementation should be limited to those with circulating 25(OH)D levels below a threshold. Evidence from randomized controlled trials (RCTs) was pri- oritized for the systematic reviews. Large (> 1000 participants) longitudinal observational cohort studies were considered if they included appropriate comparators (supplementation vs no supplementation) and outcomes, but only when an insuffi- cient number of RCTs was available. Trials where the interven- tion was a vitamin D analog or metabolite other than vitamin D2 or vitamin D3 were excluded because these compounds are not globally available. Mendelian randomization studies were excluded because they do not evaluate response to supplemen- tation. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology was used to assess the certainty of evidence and inform recommen- dations. The panel sought evidence relevant to all elements of the Evidence-to-Decision (EtD) framework, which included stakeholder values and preferences (including input from clin- ical experts and a patient representative), costs and other re- sources required, cost-effectiveness, acceptability, feasibility, and impact on health equity. The panel did not identify robust evidence pertinent to these EtD factors for most clinical questions. Limitations In formulating this Guideline, several challenges were encoun- tered that influenced the formulation of the final recommendations. 1. Because those with lower baseline levels of 25(OH)D are expected to benefit more from vitamin D supplemen- tation than those with higher levels (19), a major limita- tion in formulating recommendations was the paucity of RCTs addressing the efficacy and safety of vitamin D supplementation in populations with low baseline 25(OH)D levels. Average baseline levels of 25(OH)D in many large trials were in a range that most would consider adequate (eg, 31 ng/mL [78 nmol/L] in the VITAL trial) (20). In such trials, a lack of effect of vita- min D does not necessarily indicate that vitamin D does not influence the relevant outcome, but rather that the study populations had baseline levels of 25(OH)D that were adequate for the desired outcome. 2. Unlike typical trials for pharmacologic agents, in which control participants are not exposed to the intervention, all participants in vitamin D trials were routinely ex- posed to vitamin D through sun exposure and dietary sources. In addition, many trials allowed participants to remain on their current supplements that contained vitamin D which often reflected the DRI (eg, 600-800 IU [15-20 μg] daily for adults). Such circumstances may have biased trial results toward the null hypothesis. 3. Most vitamin D trials did not include a specific 25(OH) D level as an eligibility criterion, and no trials were de- signed or powered to address the effect of vitamin D in subgroups stratified by either baseline or achieved 25(OH)D levels. This prevented the panel from propos- ing thresholds for 25(OH)D adequacy or providing tar- get 25(OH)D levels for disease prevention, especially since 25(OH)D thresholds are likely to vary by popula- tion and outcome. Although many systematic reviews include subgroup analyses according to the study aver- age baseline 25(OH)D levels, such analyses are subject to ecological fallacy in which inferences about individu- als are based on aggregate group data. Therefore, the commissioned systematic review informing this guide- line does not include study subgroup analyses according to average baseline 25(OH)D levels. 4. Many trials were considered to be of insufficient duration to adequately assess the effect of the vitamin D interven- tion on some outcomes, due to the long latency for the de- velopment of chronic diseases such as cancer, diabetes, cardiovascular disease (CVD) and osteoporosis. 5. Because the included trials used various doses and ad- ministration schedules of vitamin D, specific dose rec- ommendations for vitamin D could not be proposed for specific populations. Instead, in the technical re- marks, vitamin D doses used in the included trials are summarized. 6. The trials that the panel considered were performed in overall healthy populations at average risk for the out- comes of interest; therefore, the recommendations are lim- ited to generally healthy individuals without established indications for vitamin D treatment or 25(OH)D testing. 7. In most trials, study participants were largely of European ancestry or identified as non-Hispanic White, with very few trials including large numbers of participants from other races or ethnicities. 8. The panel developed clinical questions for different age groups of adults (<50 years, 50 to 74 years, and 75 years and older) to represent different stages of life. However, the panel recognizes the somewhat arbitrary nature of these categories and acknowledges that many trials in- cluded populations that spanned these age categories. As a result, it was challenging to directly apply study re- sults to narrowly defined age groups. 9. Many trials in those aged older than 50 years combined vitamin D with calcium, making it difficult to isolate the effect of vitamin D from that of calcium. This is especially relevant to outcomes related to skeletal health, for which both vitamin D and calcium are considered essential. 10. Due to resource limitations, not all potential outcomes of interest were addressed in all populations of interest. The panel prioritized outcomes that they felt were most relevant to the specific populations under consideration. Thus, these clinical guidelines relate to the use of vitamin D to lower the risk of disease in individuals without established indi- cations for vitamin D treatment or 25(OH)D testing. The Guideline Development Panel assumed that the Institute of Medicine’s (IOM, now known as the National Academy of Medicine) DRIs for vitamin D (21) represent a baseline standard for all individuals. Importantly, the panel’s recommendations The Journal of Clinical Endocrinology & Metabolism, 2024, Vol. 00, No. 0 3

Page 4

should not be extrapolated to those with underlying medical conditions that are known to negatively impact vitamin D physi- ology. For those living in countries where food fortification with vitamin D is not standard or where dietary supplements are not routinely used, interventions may be required to insure a baseline intake consistent with the IOM DRIs. List of Recommendations Question 1. Should empiric vitamin D supplementation vs no empiric vitamin D supplementation be used for chil- dren and adolescents (ages 1 to 18 years)? Recommendation 1 In children and adolescents aged 1 to 18 years, we suggest empiric vitamin D supplementation to pre- vent nutritional rickets and potentially lower the risk of respiratory tract infections. (2 | ⊕⊕◯◯) Technical remarks • Empiric vitamin D may include daily intake of forti- fied foods, vitamin formulations that contain vitamin D, and/or daily intake of a vitamin D supplement (pill or drops). • In the clinical trials included in the systematic re- view, with respect to respiratory tract infections in children, vitamin D dosages ranged from 300 to 2000 IU (7.5 to 50 μg) daily equivalent. The esti- mated weighted average was approximately 1200 IU (30 μg) per day. Question 2. Should empiric vitamin D supplementation vs no empiric vitamin D supplementation be used for non- pregnant adults < 50 years of age? Question 3. Should vitamin D supplementation vs no vita- min D supplementation be used for nonpregnant adults < 50 years of age only when 25(OH)D levels are below a threshold? Recommendation 2 In the general adult population younger than age 50 years, we suggest against empiric vitamin D sup- plementation. (2 | ⊕◯◯◯) Technical remark • This recommendation relates to empiric vitamin D supplementation that exceeds the DRIs established by the IOM. Adults in this age group should follow the Recommended Daily Allowance established by the IOM (600 IU [15 μg] daily). Recommendation 3 In the general adult population younger than age 50 years, we suggest against routine 25(OH)D testing. (2 | ⊕◯◯◯) Technical remarks • In this population, 25(OH)D levels that provide outcome-specific benefits have not been estab- lished in clinical trials. • The panel suggests against (a) routine screening for a 25(OH)D level to guide decision-making (ie, vitamin D vs no vitamin D) and (b) routine follow- up testing for 25(OH)D level to guide vitamin D dosing. • This recommendation relates to generally healthy adults who do not otherwise have established in- dications for 25(OH)D testing (eg, hypocalcemia). Question 4. Should empiric vitamin D supplementation vs no empiric vitamin D supplementation be used for adults aged 50 to 74 years? Question 5. Should vitamin D supplementation vs no vita- min D supplementation be used for adults aged 50 to 74 years only when 25(OH)D levels are below a threshold? Recommendation 4 In the general population aged 50 to 74 years, we suggest against routine vitamin D supplementation. (2 | ⊕⊕⊕◯) Technical remark • This recommendation relates to empiric vitamin D supplementation that exceeds the DRIs established by the IOM. Adults in this age group should follow the Recommended Daily Allowance established by the IOM (600 IU [15 μg] daily for those aged 50 to 70 years; 800 IU [20 μg] daily for those older than 70 years). Recommendation 5 In the general population aged 50 to 74 years, we sug- gest against routine 25(OH)D testing. (2 | ⊕◯◯◯) Technical remarks • In this population, 25(OH)D levels that provide out- come-specific benefits have not been established in clinical trials. 4 The Journal of Clinical Endocrinology & Metabolism, 2024, Vol. 00, No. 0

Page 5

• The panel suggests against (a) routine screening for a 25(OH)D level to guide decision-making (ie, vita- min D vs no vitamin D) and (b) routine follow-up testing for 25(OH)D level to guide vitamin D dosing. • This recommendation relates to generally healthy adults who do not otherwise have established in- dications for 25(OH)D testing (eg, hypocalcemia). Question 6. Should empiric vitamin D supplementation vs no empiric vitamin D supplementation be used by adults aged ≥ 75 years? Question 7. Should vitamin D supplementation vs no vita- min D supplementation be used by adults aged ≥ 75 years only when 25(OH)D levels are below a threshold? Recommendation 6 In the general population aged 75 years and older, we suggest empiric vitamin D supplementation because of the potential to lower the risk of mortality. (2 | ⊕⊕⊕◯) Technical remarks • Empiric vitamin D may include daily intake of forti- fied foods, vitamin formulations that contain vita- min D and/or daily intake of a vitamin D supplement. • For empiric supplementation, daily, lower-dose vitamin D is preferred over nondaily, higher doses. • In the clinical trials included in the systematic re- view that reported on the mortality outcome, vita- min D dosage ranged from 400 to 3333 IU (10 to 83 μg) daily equivalent. The estimated weighted average was approximately 900 IU (23 μg) daily. Participants in many trials were allowed to remain on their routine supplements, including up to 800 IU (20 μg) of vitamin D daily. Recommendation 7 In the general population aged 75 years and older, we suggest against routine testing for 25(OH)D levels. (2 | ⊕◯◯◯) Technical remarks • In this population, 25(OH)D thresholds that pro- vide outcome-specific benefits have not been es- tablished in clinical trials. • The panel suggests against (a) routine screening for a 25(OH)D level to guide decision-making (ie, vita- min D vs no vitamin D) and (b) routine follow-up testing for 25(OH)D level to guide vitamin D dosing. • This recommendation relates to generally healthy adults who do not otherwise have established in- dications for 25(OH)D testing (eg, hypocalcemia). Question 8. Should empiric vitamin D supplementation vs no empiric vitamin D supplementation be used during pregnancy? Question 9. Should vitamin D supplementation vs no vita- min D supplementation be used during pregnancy only when 25(OH)D levels are below a threshold? Recommendation 8 We suggest empiric vitamin D supplementation dur- ing pregnancy, given its potential to lower risk of pre- eclampsia, intra-uterine mortality, preterm birth, small-for-gestational-age (SGA) birth, and neonatal mortality. (2 | ⊕⊕◯◯) Technical remarks • This recommendation is based on evidence from trials conducted in healthy individuals during pregnancy. • Empiric vitamin D may include daily intake of forti- fied foods, prenatal vitamin formulations that con- tain vitamin D, and/or a vitamin D supplement (pills or drops). • In the clinical trials included in the systematic re- view, the vitamin D dosages ranged from 600 IU to 5000 IU (15 to 125 μg) daily equivalent, usually provided daily or weekly. The estimated weighted average was approximately 2500 IU (63 μg) per day. Recommendation 9 During pregnancy, we suggest against routine 25(OH) D testing. (2 | ⊕◯◯◯) Technical remarks • In this population, 25(OH)D levels that provide pregnancy outcome-specific benefits have not been established in clinical trials. • The panel suggests against (a) routine screening for a 25(OH)D level to guide decision-making (ie, vitamin D vs no vitamin D) and (b) routine follow- up testing for 25(OH)D level to guide vitamin D dosing. • This recommendation relates to generally healthy pregnant individuals who do not otherwise have established indications for 25(OH)D testing (eg, hypocalcemia). Question 10. Should empiric vitamin D supplementation vs no empiric vitamin D supplementation be used for adults with prediabetes (by glycemic criteria)? The Journal of Clinical Endocrinology & Metabolism, 2024, Vol. 00, No. 0 5

Tags

Doxxly editorial guide

Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline: summary, contents and background

This guide helps you understand the scope of Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline before or alongside reading the original document. It is based on the catalogue record, credited creator, source, classification and topics shown on this page. It does not replace the original work and does not invent claims about passages that Doxxly cannot verify.

Summary and overview

Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline is a 41-page documentcredited to Cleo D. Bellweather. This 2024 Endocrine Society clinical practice guideline evaluates vitamin D supplementation and 25-hydroxyvitamin D testing for disease prevention using systematic reviews and GRADE methodology. It addresses 14 clinical questions and suggests empiric supplementation for children aged 1 - 18 years, adults aged 75 years and older, pregnant individuals, and adults with high-risk prediabetes alongside lifestyle modification. It suggests against supplementation above established dietary reference intakes in generally healthy adults younger than 75 and against routine vitamin D testing without established indications. Daily lower-dose supplementation is preferred over intermittent higher doses for adults aged 50 years and older when supplementation is indicated. Optimal supplementation doses and outcome-specific blood levels remain uncertain. It appears in the Medicine & Wellbeing collection, which groups it with other material that readers may use for comparison and further study.

The item can be approached in several ways. A reader looking for a quick orientation can begin with the free five-page preview, inspect the page structure and use the metadata to judge relevance. Someone undertaking deeper research can work through the complete file, search its indexed text, record useful page references and compare its treatment of Vitamin D, Clinical practice guideline, Disease prevention, Endocrinology, Vitamin D supplementation, 25-hydroxyvitamin D testing, Pregnancy, Prediabetes, Pediatric health, Older adults, Systematic reviews, GRADE with the related resources linked below.

Rather than reducing the work to a single claim, this page treats it as a source that should be read in context. The title, creator, publication source, licence and format all help explain what kind of evidence it may offer. Readers should distinguish the original author's statements from Doxxly's catalogue description, and should cite the original edition when using the material in academic, professional or published work.

Key topics and reader takeaways

The catalogue connects this document with Vitamin D, Clinical practice guideline, Disease prevention, Endocrinology, Vitamin D supplementation, 25-hydroxyvitamin D testing, Pregnancy, Prediabetes, Pediatric health, Older adults, Systematic reviews, GRADE. These terms offer practical entry points rather than a substitute for close reading. Start by identifying the definitions, examples, arguments, tables or visual explanations attached to each topic. Then note where the creator draws connections, makes distinctions or moves from background material to a conclusion, recommendation, calculation or narrative development.

A useful reading method is to separate description from interpretation. First record what the item actually presents: names, headings, figures, formulas, quotations or stated propositions. Next consider why those details matter within the whole work. Finally compare them with another source from the same subject area. This process helps turn a long digital file into evidence that can be evaluated rather than merely skimmed.

Table of contents and reading guide

The following is an editorial content guide based on the verified catalogue topics. It is not represented as the original author's formal table of contents. Use it to organise notes while moving through the 41 pages in the player.

  1. Part 1

    Vitamin D

    Use this section of the reading guide to identify how Vitamin D appears in Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, note important terms, and connect the subject to the wider purpose of the work.

  2. Part 2

    Clinical practice guideline

    Use this section of the reading guide to identify how Clinical practice guideline appears in Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, note important terms, and connect the subject to the wider purpose of the work.

  3. Part 3

    Disease prevention

    Use this section of the reading guide to identify how Disease prevention appears in Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, note important terms, and connect the subject to the wider purpose of the work.

  4. Part 4

    Endocrinology

    Use this section of the reading guide to identify how Endocrinology appears in Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, note important terms, and connect the subject to the wider purpose of the work.

  5. Part 5

    Vitamin D supplementation

    Use this section of the reading guide to identify how Vitamin D supplementation appears in Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, note important terms, and connect the subject to the wider purpose of the work.

  6. Part 6

    25-hydroxyvitamin D testing

    Use this section of the reading guide to identify how 25-hydroxyvitamin D testing appears in Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, note important terms, and connect the subject to the wider purpose of the work.

  7. Part 7

    Pregnancy

    Use this section of the reading guide to identify how Pregnancy appears in Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, note important terms, and connect the subject to the wider purpose of the work.

  8. Part 8

    Prediabetes

    Use this section of the reading guide to identify how Prediabetes appears in Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, note important terms, and connect the subject to the wider purpose of the work.

When a heading in the original differs from this guide, follow the original heading in your citation. Page numbers can also vary between editions. Doxxly's direct page field is useful for navigation, but formal references should include the title, creator, source and edition details available in the file itself.

About Cleo D. Bellweather

Doxxly credits Cleo D. Bellweather as the author or creator of Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. This page does not add an unverified biography, job title or institutional affiliation. The attribution is preserved so readers can distinguish the creator from the hosting library and follow the original record when an external author link is available.

Author context matters because a work reflects a particular purpose, audience and point of view. Before relying on the material, consider what the creator set out to explain, when the source was produced and whether later research or revised guidance should also be consulted. For literature and philosophy, compare translations and editions; for technical material, check whether a newer version has superseded the one shown here.

About the source organisation

The recorded source for this item is sochob.cl. Doxxly provides access and discovery tools but does not claim to be the original publisher unless explicitly stated. Source links, creator attribution and the recorded Publicly available file collected for editorial review licence are displayed to help readers assess provenance and permitted use.

Provenance is especially important for reports, standards, presentations and working spreadsheets. Check the original source for amendments, supporting files and current policy. A trustworthy research workflow keeps the source URL with any notes or downloaded copy, verifies important figures against the original, and avoids treating an archived document as automatically current.

Visit sochob.cl

How to read and use this document

Begin with the title and opening pages, then use the guide above to decide whether to read sequentially or move to a particular topic. The Doxxly player provides previous and next navigation, a direct page field, zoom steps, fit-to-width and fit-to-page modes, rotation and fullscreen. These controls are useful when a page contains small type, a wide table, an image, a scanned layout or a dense sequence of notes.

The first five pages are open to every visitor. A plan unlocks the complete item and full-document search. Search is best used for distinctive names, technical terms or short phrases; broad words can produce too many possible contexts. When you find a useful passage, read the surrounding pages so that a sentence, chart or formula is not separated from its explanation.

If downloading is enabled, members can obtain the original PDF file. Keep the original format when formulas, slide sequencing, pagination or layout carries meaning. Respect the Publicly available file collected for editorial review terms displayed on this page, and use the rights-report link if you believe the attribution or availability needs review.

Research questions to consider

As you read Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, ask which audience the creator addresses, what problem or idea organises the work, what evidence is presented, and which assumptions remain unstated. Note whether important terms are defined consistently and whether examples represent a broader pattern or a narrow case. For quantitative material, record units, time periods, formulas and data sources. For interpretive material, separate the creator's language from your own summary.

A second set of questions concerns relevance today. Which parts remain durable, which depend on their historical or institutional setting, and what would need confirmation from a newer source? Following the tags and the Medicine & Wellbeing collection can reveal useful comparisons. Agreement between sources can strengthen confidence, while disagreement can point to changing definitions, methods, evidence or priorities.

Finally, decide what you need from the item: background knowledge, a quotation, a worked example, a model, a visual explanation or a starting bibliography. That purpose should guide the depth of reading and the notes you keep. Doxxly helps locate and navigate the source; careful interpretation remains the reader's responsibility.

Explore more Medicine & Wellbeing resources

Frequently asked questions about Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline

Practical answers about reading, downloading and understanding this document on Doxxly.

More in Medicine & Wellbeing